In 23 patients with RET-altered solid tumors excluding NSCLC and thyroid cancer, pralsetinib achieved an ORR of 57% (95% CI: 35–77), mDOR of 11.7 months (95% CI: 5.5–19.0), mPFS of 7 months (95% CI: 5.1–13.6), and mOS of 13.6 months (95% CI: 7.5–NR) [28]. This evidence concerns the gene RET and thyroid cancer.